Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The EVE-PMS Diagnostic Skin Test Panel and Solvent is a diagnostic and control component of the EVE-PMS technology developed by EVE Medical Systems Ltd. for the management of severe premenstrual syndrome (PMS). The diagnostic panel consists of four sex hormones—progesterone, estradiol, estrone, and estriol—dissolved in a solvent of ethyl oleate and 10% benzyl alcohol. It is utilized to identify specific hormone hypersensitivities in women by observing skin reactions following intradermal administration during the luteal phase of the menstrual cycle. In the specific 'Skin test panel and solvent' protocol, the diagnostic testing is followed by a control treatment phase where patients receive intradermal injections of the solvent alone (ethyl oleate and benzyl alcohol) in increasing volumes, rather than the active hormone desensitization kit. This system is designed to evaluate the efficacy of hormone desensitization therapy against a negative control in reducing or eliminating PMS symptoms associated with sex hormone hypersensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EVE-PMS Diagnostic Skin Test Panel and Solvent.